China
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that it has successfully completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of NT$75 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,312.5 million (or US$42.3 million at FX=31).
Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership
Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it entered into definitive agreements with Qpex Biopharma ("Qpex") and third parties in connection with the acquisition of Qpex by Shionogi.
RevolKa Ltd.: Announcement of Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd.
TOKYO--(BUSINESS WIRE)--RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Shiro Kataoka, CEO) is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd.
Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
SAN DIEGO and SUZHOU and SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate and host investor meetings in the Truist Securities Cell Therapy Symposium: Symposia-cel on June 27, 2023, in New York, NY.
To ease cancer drug shortage, FDA will allow imports from China
The Food and Drug Administration is working with a Chinese drugmaker to import the chemotherapy drug cisplatin, a strategy aimed at ramping up supply amid an ongoing shortage of the drug in the United States.
Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
HANGZHOU and SHAOXING, China, June 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (CHB) patients with 12-week treatment at European Association for the Study of the Liver (EASL) CONGRESS 2023. The s
Adicon Holdings Ltd., a Chinese diagnostic lab, announced it will raise $52.3 million by issuing 33.2 million shares via a global offering, with shares priced at $1.57 each. Read more here.
Chinese diagnostic lab company Adicon Holdings Ltd. on Monday said it will raise HK$408.9 Million ($52.29 million) via a global offering through the issuing of 33.2 million shares.
Syngenta Wins Exchange Approval for $9.1 Billion Shanghai IPO
Syngenta Group won approval from the Shanghai stock exchange for its 65 billion yuan ($9.1 billion) initial public offering, moving the world’s biggest potential listing this year a step closer to completion.
AbbVie Says BeiGene’s Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company.
